Dolobid

(Diflunisal)

PreclinicalSmall molecule

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Dolobid is one of 62 small molecule programs targeting AL amyloidosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

AL AmyloidosisActive, not recruiting

AmyloidosisActive, not recruiting

AL AmyloidosisPhase 2/Phase 3

Active, not recruiting

AmyloidosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

76 competitors in Amyloidosis

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Phase 3

2 2

Thalomid

Bristol-Myers Squibb

Phase 3

2 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

8 4

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

5 5

Decadron

AAspen Global Incorporated

Phase 2

27 6

Darzalex

Johnson & Johnson

Phase 2

6 7

Onpattro

Alnylam Pharmaceuticals

Phase 2

5 8

Venclexta

AbbVie

Phase 2

4 9

Velcade

SShilpa Grover, MD, MPH

Alkeran

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pilot Study1 trial

Pilot Study of Diflunisal in HIV-infected Adults

Terminated·UUniversity of British Columbia·Phase 4·NCT01676363·8 enrolled

AL amyloidosis1 trial

The Effect of Diflunisal on Familial Amyloidosis

Completed·—·Phase 2/3·NCT00294671·130 enrolled

Amyloidosis1 trial

The Effect of Diflunisal on Familial Transthyretin Amyloidosis

Completed·UUmeå University··NCT01432587·55 enrolled

ART1 trial

The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04113668·48 enrolled

Regulatory

FDA Approval Timeline[4]

Apr 19, 1982

DOLOBID

NDA NDA018445

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Diflunisal. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Diflunisal compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Diflunisal. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018445). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Dolobid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pilot Study1 trial

AL amyloidosis1 trial

Amyloidosis1 trial

ART1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News